¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"macrophage migration inhibition test"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® stress test ÇÑ±Û ½ºÆ®·¹½º °Ë»ç
¼³¸í   
  Çù½ÉÁõÀÌ ÀϾ±â ½¬¿î È¯ÀÚ¿¡°Ô¼­ ±× Á¤µµ¸¦ ÆÇ´ÜÇϱâÀ§ÇØ ½ÃÇàÇÑ´Ù. ¹æ¹ýÀº °°Àº °÷¿¡¼­ È¯ÀÚ¸¦ ´Þ¸®µµ·Ï ÇÑ ´ÙÀ½, ¾ó¸¶ÀÇ ¼Óµµ¿¡¼­ Ç÷¾ÐÀÌ ¶³¾îÁö°í Çù½ÉÁõ Áõ»óÀÌ ³ªÅ¸³ª´Â°¡¸¦ °Ë»çÇÑ´Ù.
  
  ´ë°³ ½ÉÇÒ¼ö·Ï ³·Àº ¼Óµµ¿¡¼­µµ Áõ»óÀÌ »¡¸® ³ªÅ¸³­´Ù.
¿µ¹® visual field test ÇÑ±Û ½Ã¾ß°Ë»ç
¼³¸í   
  ´«À» ÇѰ÷¿¡ °íÁ¤½ÃŲ Ã¤, °üÂûÇÒ ¼ö Àִ ÁÖº¯°ø°£À» ½Ã¾ß¶ó ÇÑ´Ù. ½Ã¾ß¸¦ °Ë»çÇϴ °¡Àå °£´ÜÇÑ ¹æ¹ýÀº ´ë¸é°Ë»ç(confronting test)ÀÌ´Ù. À̰ÍÀº Çǰ˻çÀÚÀÇ ´«À» °Ë»çÀÚÀÇ ´«¿¡ ¸ÂÃ߾¸µµ·Ï ÇÏ¿© ´«À» °íÁ¤½ÃŲä, °Ë»çÀÚ°¡ ¼Õ°¡¶ô³¡À» À§ÂÊ, ¾Æ·¡ÂÊ, ¿ÞÂÊ, ¿À¸¥ÂÊ, ±×¸®°í ºñ½ºµëÈ÷ °æ»çÁø °÷ µîÀ¸·Î ¿Å°Üº¸¾Æ Çǰ˻çÀÚ°¡ °üÂûÇÒ ¼ö ÀÖ´ÂÁö ¿©ºÎ¸¦ Á¤Çϴ °Ë»ç¹ýÀÌ´Ù. À̺¸´Ù Á¤È®ÇÑ °Ë»ç¹ýÀº ÀÚµ¿½Ä ÄÄÇ»Åͽþ߰˻ç¹ýÀÌ ÀÖ´Ù. ´ë°³, ´«ÀÚüÀÇ ÀÌ»óÀÌ À־ ½Ã¾ß°Ë»ç¿¡¼­ ÀÌ»óÀÌ ³ª¿ÀÁö¸¸, À̿ܠ³úÀÇ ÀÌ»óÀ¸·Î ½Ã°¢ÀÇ Çü¼º°æ·Î¿¡ ÀÌ»óÀÌ À־ ¿ª½Ã ÀÌ»ó¼Ò°ßÀ» º¸ÀδÙ.
¿µ¹® Draw a person test ÇÑ±Û Àι°È­ ¼º°Ý°Ë»ç
¼³¸í   
  Àι°È­ ¼º°Ý°Ë»ç´Â Ã³À½¿¡´Â Áö´É°Ë»ç·Î °³¹ßµÇ¾ú°í, ±× ÈÄ¿¡´Â »ç¶÷ÀÇ ¹«ÀǽÄÀÇ ¿ä¼Ò¸¦ °Ë»çÇϴ ¹æ¹ýÀ¸·Î ¹ßÀüÇÏ¿´´Ù. °Ë»çÀç·á´Â Áö¿ì°³°¡ Àִ ¿¬Çʰú ¹éÁö¸¦ ÇǰËÀÚ¿¡°Ô ÁÖ°í, »ç¶÷À» ±×·Áº¸¶ó´Â Áö½Ã¸¦ Çϸç, °Ë»çÀڴ ±×¸®´Â ¼ø¼­¿Í Æò°¡¸¦ ±â·ÏÇϰí, ´Ù ±×¸° ÈÄ¿¡´Â ¸ÕÀú¿Í ´Ù¸¥ À̼ºÀ» ±×¸®µµ·Ï ÇÑ´Ù. ÀÌ °Ë»ç¿¡¼­ÀÇ ½ÅüÀÇ ¸ð¾çÀº °ð ÀھƻóÀ» ¹Ý¿µÇѴٴ ÀÔÀå, ±×¸²¿¡¼­ °­Á¶µÈ ±â°üÀº ÀÇ»ç¼ÒÅë¼ö´Ü, °ü³äÈ­, ¿å±¸Ã¼°è, ¼ºÀû ´É·Â, °¥µî, ÁÂÀý°æÇè, ¼ºÀå·Â µîÀ» ¹Ý¿µÇÑ´Ù°í ÇÑ´Ù. À̰ÍÀº ¾Æµ¿°ú ¼ºÀο¡°Ô °³º°Àû ¶Ç´Â Áý´ÜÀûÀ¸·Î ½Ç½ÃÇÒ ¼ö ÀÖ°í, °£ÆíÇϸ鼭µµ À¯ÀÍÇÑ °ÍÀÌ´Ù. ÀÓ»óÀûÀ¸·Î´Â ³úÀÇ ±âÁúÀû º¯È­¸¦ ¾Ë¾Æ³»±â À§ÇÑ ¸ñÀûÀ¸·Îµµ ¸¹ÀÌ ÀÌ¿ëµÈ´Ù.
¿µ¹® intelligence test ÇÑ±Û Áö´É°Ë»ç
¼³¸í   
  1905³â ÇÁ¶û½ºÀÇ ºñ³×°¡ Á¤½Å¹Ú¾à¾Æ¸¦ ÀϹݾƵ¿À¸·ÎºÎÅÍ ÆÇº°Çϱâ À§ÇÏ¿© ÀÛ¼ºÇÑ °ÍÀÌ Áö´É°Ë»çÀÇ ½ÃÀÛÀÌ´Ù. Áö´É°Ë»ç´Â ±×ÀÇ ¸ñÀûÀ¸·ÎºÎÅÍ ÀϹÝÀû Áö´É°Ë»ç¿Í Áø´Ü¿ë Áö´É°Ë»ç·Î ³ª´²Áö°í, ½Ç½Ã¹æ¹ý¿¡¼­ °³Àοë(°³º°½Ä)°ú Áý´Ü¿ë(´Üü½Ä)À¸·Î ºÐ·ùµÇ°í ¶Ç ¹®Á¦ÀÇ ³»¿ëÀ¸·ÎºÎÅÍ ¾ð¾î¼º°Ë»ç(A½Ä ¶Ç´Â ¥á½Ä)¿Í ºñ¾ð¾î¼º°Ë»ç(B½Ä ¥â½Ä)·Î ³ª´²Áø´Ù. Áö´É°Ë»çÀÇ °á°úÀǠǥ½Ã¹ýÀº Á¤½Å¿¬·É(mental age, MA), Áö´ÉÁö¼ö(intelligence quotient, IQ), Áö´ÉÆíÂ÷Ä¡(intelligence standard score, ISS)µîÀÌ ÀÖ´Ù. Áö´É°Ë»ç¿¡´Â ¿ª»çÀûÀ¸·Î ºñ³×½Ä°ú À°±º½ÄÀÇ µÎ °èÅëÀÌ ÀÖ´Ù. ºñ³×½ÄÀº °Ë»çÀÚ°¡ °³º°ÀûÀ¸·Î ÇÑ °³ ¹®Ç×¾¿ Áú¹®À» Çϸé ÀÌ¿¡ ´ëÇÏ¿© Çǰ˻çÀÚ°¡ ¸»À̳ª ÇൿÀ¸·Î ÀÀ´äÇϴ ¹æ¹ý(°³º°½Ä-¹®´ä½Ä)À̰í, À°±º½ÄÀº ÀϹÝÀûÀΠ¹æ½ÄÀ¸·Î´Â ÀμâµÈ ¹®Á¦¿ëÁö¸¦ »ç¿ëÇÏ¿© Çǰ˻çÀÚ°¡ ¼ÒÁ¤ÀÇ ½Ã°£ ³»¿¡ µÇµµ·Ï ¸¹ÀÌ ¹Ù¸£°Ô(½Ã°£Á¦Çѹý) È¸´äÀ» ±âÀÔÇÑ´Ù(Çʱâ¹ý). Çѱ¹ ÃÖÃÊÀÇ Áö´É°Ë»ç´Â 1954³â ¼­¿ï´ëÇб³ »ç¹ü´ëÇР±³À°½É¸®¿¬±¸½Ç¿¡¼­ Á¦ÀÛÇÑ °£Æí Áö´É°Ë»çÀÌ´Ù. °£Æí Áö´É°Ë»ç ÀÌÈÄ ´Ù¼öÀÇ Áý´Ü Áö´É°Ë»ç°¡ ÃâÇöÇÏ¿´´Âµ¥ ºñ±³Àû ÃÖ±Ù¿¡ Ç¥ÁØÈ­µÈ Áö´É°Ë»ç·Î´Â Çѱ¹Çൿ°úÇבּ¸¼Ò°¡ 1984³â¿¡ Àü±¹ °íµîÇб³ ÇлýÀ» ´ë»óÀ¸·Î Á¦ÀÛÇÑ KIT-S Áö´É°Ë»ç°¡ ÀÖ´Ù.
¿µ¹® patch test ÇÑ±Û Ã¸Æ÷°Ë»ç
¼³¸í   
  ÇǺξ˷¹¸£±â¿¡ ´ëÇÑ °Ë»ç¹æ¹ýÀ¸·Î Ç׿øÀ» ºÙÀΠøÆ÷¸¦ ÇǺο¡ ºÎÂøÇÑ ´ÙÀ½ 2ÀÏ ÈÄ¿¡ »çÇϰí, ´Ù½Ã 2ÀÏ ÈÄ¿¡ °Ë»çÇÑ´Ù. 2¹ø ¸ðµÎ ÇǺÎÀÌ»óÀÌ ³ªÅ¸³ª¸é, ¾Ë·¹¸£±â¹ÝÀÀ¿¡ ÀÇÇÑ ÀÌ»ó¼Ò°ßÀ̸ç, ¸¸¾à Ã³À½ 2ÀÏ¿¡´Â ÀÌ»óÀÌ ÀÖÁö¸¸, ´ÙÀ½ 2ÀÏ ÈÄ °Ë»ç¿¡¼­ ÀÌ»ó¼Ò°ßÀÌ ¾øÀ¸¸é, ±×°ÍÀº ´ÜÁö ÇǺÎÀڱؿ¡ ÀÇÇÑ ÀÌ»ó¼Ò°ßÀÏ »ÓÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • granulocyte-macrophage colony-stimulating factor
    °ú¸³±¸Å«Æ÷½Ä¼¼Æ÷Áý¶ôÀÚ±ØÀÎÀÚ, °ú¸³±¸´ë½Ä±¸Áý¶ôÀÚ±ØÀÎÀÚ
  • monocyte-macrophage cell system
    ´ÜÇÙ±¸Å«Æ÷½Ä¼¼Æ÷°èÅë, ´ÜÇÙ±¸´ë½Ä¼¼Æ÷°èÅë
  • macrophage
    Å«Æ÷½Ä¼¼Æ÷, ´ë½Ä¼¼Æ÷
  • macrophage aggregating factor
    Å«Æ÷½Ä¼¼Æ÷ÀÀÁýÀÎÀÚ, ´ë½Ä¼¼Æ÷ÀÀÁýÀÎÀÚ
  • macrophage arming factor
    Å«Æ÷½Ä¼¼Æ÷¹«ÀåÀÎÀÚ, ´ë½Ä¼¼Æ÷¹«ÀåÀÎÀÚ
  • macrophage chemotactic factor
    Å«Æ÷½Ä¼¼Æ÷È­Çнò¸²ÀÎÀÚ, ´ë½Ä¼¼Æ÷È­Çнò¸²ÀÎÀÚ
  • macrophage colony-stimulating factor
    Å«Æ÷½Ä¼¼Æ÷Áý¶ôÀÚ±ØÀÎÀÚ, ´ë½Ä¼¼Æ÷Áý¶ôÀÚ±ØÀÎÀÚ
  • macrophage system
    Å«Æ÷½Ä¼¼Æ÷°èÅë, ´ë½Ä¼¼Æ÷°è
  • macrophage-activating factor
    Å«Æ÷½Ä¼¼Æ÷Ȱ¼ºÀÎÀÚ, ´ë½Ä¼¼Æ÷Ȱ¼ºÀÎÀÚ
  • macrophage-derived growth factor
    Å«Æ÷½Ä¼¼Æ÷À¯·¡¼ºÀåÀÎÀÚ, ´ë½Ä¼¼Æ÷À¯·¡¼ºÀåÀÎÀÚ
  • resident macrophage
    »óÁÖÅ«Æ÷½Ä¼¼Æ÷, »óÁÖ´ë½Ä¼¼Æ÷
  • antidromic inhibition
    ¿ª¹æÇâ¾ïÁ¦
  • afferent inhibition
    µé½Å°æ¾ïÁ¦, ±¸½É¾ïÁ¦
  • allogenic inhibition
    µ¿Á¾ÀÌÇü¾ïÁ¦
  • competitive inhibition
    °æÀï¾ïÁ¦
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antiglobulin test
    Çױ۷κҸ°°Ë»ç
  • antimicrobial susceptibility test
    Ç×±ÕÁ¦°¨¼ö¼º°Ë»ç
  • blood test
    Ç÷¾×°Ë»ç
  • blood coagulation test
    Ç÷¾×ÀÀ°í°Ë»ç
  • blood sugar test
    Ç÷´ç°Ë»ç
  • bronchial provocation test
    ±â°üÁöÀ¯¹ß°Ë»ç
  • contraction stress test
    ¼öÃàÀڱذ˻ç
  • Coombs' test
    (¢¡antiglobulin test) ÄñÁî°Ë»ç
  • creatinine clearance test
    Å©·¹¾ÆÆ¼´Ñû¼ÒÀ²°Ë»ç
  • D-xylose test
    Å©½Ç·Î¿À½º°Ë»ç
  • dip-stick test
    ¿ä½ÃÇèÁö°Ë»ç
  • estrogen challenge test
    ¿©¼ºÈ£¸£¸óºÎÇϰ˻ç
  • flashlight swinging test
    ±³´ëºÒºû°Ë»ç
  • glucose tolerance test
    ´çºÎÇϰ˻ç
  • guaiac test
    ÀáÇ÷°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • dendritic macrophage
    °¡Áöµ¹±âÅ«Æ÷½Ä¼¼Æ÷
  • fixed macrophage
    °íÁ¤Å«Æ÷½Ä¼¼Æ÷
  • foamy macrophage
    Æ÷¸»Å«Æ÷½Ä¼¼Æ÷
  • free macrophage
    ÀÚÀ¯Å«Æ÷½Ä¼¼Æ÷
  • granulocyte-macrophage colony-stimulating factor
    °ú¸³±¸Å«Æ÷½Ä¼¼Æ÷Áý¶ôÀÚ±ØÀÎÀÚ
  • macrophage aggregating factor
    Å«Æ÷½Ä¼¼Æ÷ÀÀÁýÀÎÀÚ
  • macrophage arming factor
    Å«Æ÷½Ä¼¼Æ÷¹«ÀåÀÎÀÚ
  • macrophage chemotactic factor
    Å«Æ÷½Ä¼¼Æ÷È­ÇÐÁÖ¼ºÀÎÀÚ, Å«Æ÷½Ä¼¼Æ÷È­Çнò¸²ÀÎÀÚ
  • macrophage colony-stimulating factor
    Å«Æ÷½Ä¼¼Æ÷Áý¶ôÀÚ±ØÀÎÀÚ
  • macrophage-activating factor
    Å«Æ÷½Ä¼¼Æ÷Ȱ¼ºÀÎÀÚ
  • macrophage-derived growth factor
    Å«Æ÷½Ä¼¼Æ÷À¯·¡¼ºÀåÀÎÀÚ
  • macrophage
    Å«Æ÷½Ä¼¼Æ÷, ´ë½Ä¼¼Æ÷
  • macrophage system
    Å«Æ÷½Ä¼¼Æ÷°èÅë
  • monocyte-macrophage cell system
    ´ÜÇÙ±¸Å«Æ÷½Ä¼¼Æ÷°èÅë
  • resident macrophage
    Åä¹ÚÀÌÅ«Æ÷½Ä¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hemagglutination inhibition test =HIT
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè.
  • hemagglutination-inhibition (HI) test
    Ç÷±¸ÀÀÁý ÀúÁö½ÃÇè
  • inhibition test
    ÀúÁö½ÃÇè(îÁò­ãËúÐ).
  • inhibition test
    ¾ïÁ¦½ÃÇè
  • inhibition test, agglutination
    ÀÀÁý¾ïÁ¦½ÃÇè, ÀÀÁýÀúÁö½ÃÇè
  • inhibition test, antiglobulin
    Çױ۷κҸ° ¾ïÁ¦½ÃÇè, Çױ۷κҸ° ÀúÁö½ÃÇè
  • inhibition test, fluorescence
    Çü±¤¾ïÁ¦½ÃÇè, Çü±¤ÀúÁö½ÃÇè
  • inhibition test, hemagglutination
    Ç÷±¸ÀÀÁý ¾ïÁ¦½ÃÇè, Ç÷±¸ÀÀÁý ÀúÁö½ÃÇè
  • Internal inhibition
    ³»ºÎ¾ïÁ¦(Үݻåäð¤)
  • Lateral inhibition
    ÃøºÎ¾ïÁ¦(ö°Ý»åäð¤)
  • PETINIA => particle-enhanced turbidimetric inhibition immunoassay
    ÀÔÀÚÁõ´ëºñʾïÁ¦¸é¿ªÃøÁ¤(¹ý)
  • afferent inhibition
    ±¸½É¼º ¾ïÁ¦(Ï´ãýàõåäð¤)
  • allogen(a)ic inhibition
    µ¿Á¾¼¼Æ÷ÀúÁö(¡­á¬øàðæò­).
  • antidromic inhibition
    ¿ª¹æÇ⼺ ¾ïÁ¦ (¡­åäð¤)
  • group Ia inhibition
    ¥°a¤ÇϹA.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • migration
    ÀÌÁÖ
  • migration defect
    ÀÌÁÖ°áÇÔ
  • migration inhibitory factor =MIF
    ´ë½Ä¼¼Æ÷À¯ÁÖÀúÁöÀÎÀÚ(ÓÞãÝá¬øàë´ñËîÁ ò­ì×í­).
  • migration potential
    À̵¿ÀüÀ§.
  • agar gel precipitin inhibition test
    ÇÑõ°Öħ°­¼Ò ÀúÁö½ÃÇè(¡­ ˽áÈðæò­ãËúÐ).
  • agglutination inhibition test
    ÀÀÁý¾ïÁ¦½ÃÇè(¡­åäð¤ãËúÐ).
  • colony inhibition test
    Áý¶ôÇü¼º ÀúÁö½ÃÇè, ¼¼Æ÷±ºÇü¼º ÀúÁö½ÃÇè
  • complement fixation inhibition test
    º¸Ã¼°íÁ¤ÀúÇØ½ÃÇè(ÜÍô÷ͳïÒîÁúªãËúÐ).
  • complement fixation inhibition test
    º¸Ã¼°áÇÕÀúÇØ½ÃÇè(ÜÍô÷Ì¿ùêîÁúªãËúÐ).
  • fluoresence inhibition test
    Çü±¤¾ïÁ¦½ÃÇè, Çü±¤ÀúÁö½ÃÇè
  • haemagglutination inhibition test
    Ç÷±¸ÀÀÁýÀúÁö½ÃÇè(¡­îÁò­ãËúÐ).
  • haemagglutination inhibition test
    Ç÷±¸ÀÀÁýÀúÁö½ÃÇè(?Ëø?ËàÌ´).
  • hemagglutination inhibition test
    Ç÷±¸ÀÀÁý ÀúÁö½ÃÇè
  • hemagglutination inhibition test
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè
  • hemagglutination inhibition test =HIT
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • competitive inhibition
    °æÇÕÀúÇØ(ÌæùêîÁúª)
  • concerted divalent inhibition
    Çùµ¿ À̰¡ ÀúÇØ(úðÔÒì£Ê¤îÁúª)
  • concerted feedback inhibition
    Çùµ¿(úðÔÒ) µÇ¸ÔÀÓ ÀúÇØ(îÁúª)
  • contact inhibition
    Á¢ÃËÀúÇØ(ïÈõºîÁúª)
  • cooperative feedback inhibition
    Çùµ¿(úðÔÒ) µÇ¸ÔÀÓÀúÇØ(îÁúª)
  • coupling inhibition
    "¦Áþ±â ÀúÇØ(îÁúª), (ÔÒ) uncompetitive inhibition"
  • cumulative feedback inhibition
    ´©Àû(׫îÝ) µÇ¸ÔÀÓ ÀúÇØ(îÁúª)
  • density inhibition
    "¹ÐµµÀúÇØ(ÚËÓøîÁúª), (ÔÒ) contact inhibition"
  • end-product inhibition
    Á¾»ê¹° ÀúÇØ (ðûß§ÚªîÁúª)
  • enzyme multiplicity feedback inhibition
    È¿¼Ò ´Ù¾ç¼º(ý£áÈÒýåÆàõ) µÇ¸ÔÀÓ ÀúÇØ(îÁúª)
  • feedback inhibition
    µÇ¸ÔÀÓ ÀúÇØ(îÁúª)
  • hemagglutination inhibition
    "(Àû,îå)Ç÷±¸(úìϹ) ÀÀÁý ÀúÇØ(ëêó¢îÁúª)"
  • hyperbolic inhibition
    ½Ö°î¼± ÀúÇØ(äªÍØàÊîÁúª)
  • immunological inhibition
    ¸é¿ª ÀúÇØ(Øóæ¹îÁúª)
  • inhibition
    ÀúÇØ(îÁúª)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • provocative test
    À¯¹ß½ÃÇè
  • pulmonary function test
    Æó±â´É°Ë»ç
  • qualitative test
    Á¤¼º½ÃÇè
  • respiratory function test
    È£Èí±â´É°Ë»ç
  • routine test
    »ó¿ë Å×½ºÆ®
  • screening test
    ¼±º°°Ë»ç, ¿¹ºñ°Ë»ç
  • serologic test
    Ç÷û(ÇÐÀû)°Ë»ç
  • sigle blind test
    ´ÜÀϸͽÃÇè
  • skin test
    ÇǺÎ(¹ÝÀÀ)°Ë»ç
  • supression test
    ¾ïÁ¦°Ë»ç
  • test
    ½ÃÇè, °Ë»ç(¹ý)
  • test object
    ½ÃÇè´ë»ó, Ç¥½Ä¹°
  • test phantom
    Ç¥ÁØÆÒÅÒ
  • test phase
    ½ÃÇè±â
  • thymol turbidity test
    Ƽ¸ôȥʽÃÇè
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
DMI Defense Mechanism Inventory; Diagnostic Medical Instruments; diaphragmatic myocardial infarction; di...
LMI leukocyte migration inhibition
LMIF leukocyte migration inhibition factor
PAT Pain Apperception Test; paroxysmal atrial tachycardia; patient; phenylaminotetrazole; physical abili...
MIT Massachusetts Institute of Technology; male impotence test; marrow iron turnover; melodic intonation...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LMIF Leukocyte migration inhibition factor
MIF Migration Inhibition Factor
MI Migration inhibition
LMT Leucocyte Migration Test
LMT Leucocyte migration inhibiton test
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • peritoneal macrophage
    º¹°­ ´ë½Ä ¼¼Æ÷, º¹°­ °Å½Ä ¼¼Æ÷
  • resident macrophage
    »óÁÖ ´ë½Ä ¼¼Æ÷
  • allogeneic inhibition
    µ¿Á¾ ÀÌÇü ¾ïÁ¦
  • antagonistic inhibition
    ±æÇ×±Ù ¾ïÁ¦, ±æÇ×Àû ¾ïÁ¦, ±æÇ×Àû ÀúÇØ
  • antidromic inhibition
    ¿ª¹æÇ⼺ ¾ïÁ¦
  • competitive inhibition
    °æÀïÀû ¾ïÁ¦, °æÇÕ¼º ¾ïÁ¦
    ¾î¶² ¼ö¿ëü¿¡ ´ëÇØ °áÇÕ·ÂÀÌ Å« ¹°ÁúÀÌ »ó´ëÀûÀ¸·Î °áÇÕ·ÂÀÌ ¾àÇÑ ´Ù¸¥ ¹°ÁúÀÇ °áÇÕÀ» ¾ïÁ¦ÇÏ´Â °Í.
  • cyto- ¼¼Æ÷¿ÍÀÇ °ü°è¸¦ ³ªÅ¸³»´Â Á¢µÎ¾î.

    cyto-inhibition

    ¼¼Æ÷ ¾ïÁ¦ ÀÛ¿ë
    ޽ÄÇÑ ¼¼±Õ ¶Ç´Â ¹ÙÀÌ·¯½º¸¦ ¿ëÇØÇϰųª È­Çпä¹ýÁ¦¿¡ ÀÇÇÑ È­ÇÐÀû ÆÄ±«·ÎºÎÅÍ ¹æ¾îÇÏ´Â ½Ä ¼¼Æ÷ÀÇ ÀÛ¿ë.
  • enzyme inhibition
    È¿¼Ò ¾ïÁ¦
  • inhibition
    ¾ïÁ¦, ÀúÁö, ÀúÇØ
    °úÁ¤ÀÇ ¾ï¾Ð
  • inhibition reaction
    ¾ïÁ¦, ¾ïÁ¦ ¹ÝÀÀ, ÀúÁö, ÀúÁö ¹ÝÀÀ
  • inhibition zone
    ¾ïÁ¦´ë
    ħ°­ ¶Ç´Â ÀÀÁý ¹ÝÀÀ¿¡¼­ Ç×ü ³óµµ°¡ ³ôÀº Ç÷û¿¡¼­´Â Ç׿ø ÀÔÀÚ¿Í ¹ÝÀÀÀ» ³ªÅ¸³»Áö ¾Ê´Â Çö»ó.
  • lateral inhibition
    Ãø¹æ ¾ïÁ¦
    ÈïºÐÇϰí ÀÖ´Â ¿ä¼Ò¿¡ ÀÇÇÏ¿© ÀÎÁ¢ÇÏ´Â ¿ä¼ÒÀÇ È°µ¿ÀÌ ¾ïÁ¦µÇ´Â Çö»ó.
  • lingering inhibition

    lingissimus capitis (µÎÃÖÀå±Ù

    »óÃø 4¡­5 ÈäÃßÀÇ È¾µ¹±â¿Í ÇÏÃø 3¡­4 °æÃßÀÇ °üÀýµ¹±â¿¡¼­ ±â½ÃÇÏ¿© ÃøµÎ°ñÀÇ À¯¾çµ¹±â¿¡¼­ Á¤ÁöÇÑ´Ù. °æ ½Å°æ °¡ÁöÀÇ Áö¹è¸¦ ¹ÞÀ¸¸ç, ¸Ó¸®¸¦ ÈĹæÀ¸·Î ´ç±â°í ȸÀü½ÃŲ´Ù.
  • myelinated afferent inhibition
    À¯¼öÃÊ ±¸½É¼º ¾ïÁ¦
  • negative feedback inhibition
    À½¼º µÇ¸ÔÀ̱⠾ïÁ¦
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
leukocyte migration-inhibitory factors Protein factor(s) released by sensitised lymphocytes (and possibly other cells) that inhibit the movement of leukocytes, especially polymorphonuclear cells, away from their site of release. Assays for these factors are used as tests for cellular immunity. Two of the common assays are the leukocyte migration capillary tube technique (lmct) and the leukocyte migration agarose technique (lmat).
(12 Dec 1998)
activated macrophage A mature macrophage, in an active metabolic state, that is cytotoxic to tumour/target cells, usually following exposure to certain cytokines.
Synonym: armed macrophage.
(05 Mar 2000)
alveolar macrophage Macrophage found in lung and that can be obtained by lung lavage, responsible for clearance of inhaled particles and lung surfactant. Metabolism slightly different from peritoneal macrophages (more oxidative metabolism), often have multivesicular bodies that may represent residual undigested lung surfactant.
(18 Nov 1997)
alveolar macrophage elastase <enzyme> Metalloproteinase found in human alveolar macrophages
Registry number: EC 3.4.24.-
Synonym: elastase, alveolar macrophage, metalloproteinase elastase, human macrophage metalloelastase, mmp12 gene product, mmp-12 gene product, mme gene product, macrophage metalloelastase
(26 Jun 1999)
armed macrophage A mature macrophage, in an active metabolic state, that is cytotoxic to tumour/target cells, usually following exposure to certain cytokines.
Synonym: armed macrophage.
(05 Mar 2000)
associated macrophage A mature macrophage in an active metabolic state that is cytotoxic to tumour/target cells, usually following exposure to certain cytokines.
(05 Mar 2000)
macrophage Relatively long lived phagocytic cell of mammalian tissues, derived from blood monocyte. Macrophages from different sites have distinctly different properties. Main types are peritoneal and alveolar macrophages, tissue macrophages (histiocytes), Kupffer cells of the liver and osteoclasts. In response to foreign materials may become stimulated or activated. Macrophages play an important role in killing of some bacteria, protozoa and tumour cells, release substances that stimulate other cells of the immune system and are involved in antigen presentation. May further differentiate within chronic inflammatory lesions to epithelioid cells or may fuse to form foreign body giant cells or Langhans giant cells.
(18 Nov 1997)
macrophage-1 antigen An adhesion-promoting leukocyte surface membrane heterodimer. The alpha subunit consists of the CD11b antigen and the beta subunit of the CD18 antigen (antigens, CD18). The antigen, which is an integrin, functions both as a receptor for complement 3 and in cell-cell and cell-substrate adhesive interactions.
(12 Dec 1998)
macrophage-activating factor An agent that stimulates macrophages to attack and ingest cancer cells. They are secreted by stimulated lymphocytes that prime macrophages to become non-specifically cytotoxic to tumours.
They also modulate the expression of macrophage cell surface ia antigens. One maf is interferon-gamma (interferon type II). Other factors antigenically distinct from ifn-gamma have also been identified.
(12 Dec 1998)
macrophage activation The process of altering the morphology and functional activity of macrophages so that they become avidly phagocytic. It is initiated by lymphokines, such as the macrophage activation factor (maf) and the macrophage migration-inhibitory factor (mmif), immune complexes, c3b, and various peptides, polysaccharides, and immunologic adjuvants.
(12 Dec 1998)
macrophage colony-stimulating factor <growth factor> A glycoprotein growth factor that causes the committed cell line to proliferate and mature into macrophages.
A cytokine synthesised by mesenchymal cells that stimulates pluripotent stem cells of bone marrow into differentiating towards the production of monocytes (mononuclear phagocytes).
The compound stimulates the survival, proliferation, and differentiation of haematopoietic cells of the monocyte-macrophage series. It is a disulfide-bonded glycoprotein dimer with a mw of 70 kD and binds to a single class of high affinity receptor which is identical to the product of the c-fms proto-oncogene.
See: colony-stimulating factors.
Chemical name: Colony-stimulating factor 1
Acronym: M-CSF
(12 Dec 1998)
macrophage inflammatory protein <cytokine> A chemokine that is chemotactic for neutrophils and monocytes, stimulates macrophages, and may play a role in regulating haematopoiesis. Its two variants, mip-1alpha and mip-1beta, are 60% homologous to each other.
They are heparin-binding proteins that exhibit a number of inflammatory and immunoregulatory activities. Originally identified as secretory products of macrophages, these chemokines are produced by a variety of cell types including neutrophils, fibroblasts, and epithelial cells.
They most likely also play a significant role in respiratory tract defenses.
(20 Sep 2002)
receptors, granulocyte-macrophage colony-stimulating factor Receptors that bind and internalise the granulocyte-macrophage stimulating factor. Their mw is believed to be 84 kD. The most mature myelomonocytic cells, specifically human neutrophils, macrophages, and eosinophils, express the highest number of affinity receptors for this growth factor.
(12 Dec 1998)
receptors, macrophage colony-stimulating factor Glycoproteins of mw 165 kD which are encoded by the c-fms proto-oncogene. The binding of csf-1 to its receptors activates an intrinsic tyrosine kinase activity resulting in autophosphorylation of the receptors on tyrosine, rapid receptor down-regulation, and phosphorylation of as yet unidentified physiologic substrates that initiate a mitogenic response.
(12 Dec 1998)
chemotactic factors, macrophage Cytotaxins liberated from normal or invading cells that specifically attract macrophages. They may be lymphokines, products of antigen, antibody and complement interactions or other.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • blood test
    Ç÷¾×°Ë»ç
  • breath test
    ÁÖ±â°Ë»ç
  • captive test (firing)
    (¹Ì»çÀÏ.·ÎÄÏ ¿£ÁøµîÀÇ)Áö»ó ºÐ»ç ½ÃÇè
  • cartoon test
    ¾àÈ­ Å×½ºÆ®
  • completion test
    ¿Ï¼ºÇü Å×½ºÆ®
  • doping test
    ±ÝÁö ¾à¹° °Ë»ç
  • doublebline test
    ÀÌÁß¸Í °Ë»ç¹ý(½Å¾à È¿°úÀÇ °Ë»ç¹ý)
  • driving test
    ¿îÀü ¸éÇã ½ÃÇè
  • drop test
    ³«ÇÏ ½ÃÇè(Å×½ºÆ®)
  • fatigue test
    ÇÇ·Î ½ÃÇè
  • film test
    ¿µÈ­ ¹è¿ì Áö¸ÁÀÚÀÇ Ä«¸Þ¶ó Å×½ºÆ®
  • herd test
    ¼Ò¶¼ÀÇ °Ë»ç(ƯÁ¤ Á¥¼Ò¶¼ÀÇ À¯Áö¹æ ÇÔÀ¯À² °Ë»ç)
  • inkblot test
    RORSCHACH TEST
  • intelligence test
    ±â´É°Ë»ç
  • intradermal test
    (ÀÇ)Çdz»(¸é¿ª)Å×½ºÆ®
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á